Pharmacokinetics of Ganyanling Zhusheye after single intramuscular dose in healthy volunteers

Abstract

Abstract: AIM: To study the pharmacokinetics profiles of Ganyanling Zhusheye after single intramuscular dosing in healthy volunteers. METHODS: Twelve healthy vounlteers were given a single intramuscular dose of Ganyanling Zhusheye 2 mL. Matrine concentrations in plasma were determined by HPLC-MS-MS method.The pharmacokinetic parameters were obtained with statistical analysis by DAS Ver 2.0. RESULTS: Ganyanling Zhusheye disposition on intramuscular administration was characterized by a two-compartment pharmacokinetic mode. The mean pharmacokinetic parameters of healthy volunteers were t_1/2z(7.5±1.4) h,CLz/F(17±4) L/h,t_max0.5(0.33,4) h,AUC_0-t(2087±525) μg·L^-1·h, AUC_0-∞(2131±541) μg·L^-1·h,Vz/F(185±47) L, C_max (235±63) μg/L; The main pharmacokinetic parameters of rhein in female and male healthy volunteers were t_1/2z (7.1±2.0) h vs(7.8±0.6)h, CLz/F(15±4)vs(20±3) L/h(P<0.05), t_max 0.75(0.33,4 ) vs 0.5(0.33, 1) h, AUC_0-t (2396±524)vs(1816±322)μg·L^-1·h (P<0.05), AUC_0-∞(2456±549) vs(1778±322) μg·L^-1·h (P<0.05), Vz/F(149±31)vs(222±27)L(P<0.05),C_max(263±76) vs(208±31) μg/L. CONCLUSION: There is gender difference of pharmacokinetics of intramuscula Ganyanling Zhusheye in healthy volunteers.

Key words: Ganyanling Zhusheye, Matrine, HPLC-MS-MS , Pharmacokinetic

CLC Number:

R969.1

HE Min, QIU Fu-rong, GAO Cheng-lu, CHEN Qin, YANG Shu-juan, SUN Yi-jie, JIANG Jian. Pharmacokinetics of Ganyanling Zhusheye after single intramuscular dose in healthy volunteers[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1261-1266.

References

[1] 沙静姝,毛洪奎.山豆根注射液(肝炎灵注射液) [J].药学通报, 1983, 18 (10): 37.
[2] 丁佩兰, 陈道峰.中药山豆根及其制剂的药理作用、临床运用及不良反应[J].中国临床药学杂志,2003,12(5):315-318.
[3] 曾聪彦,梅全喜.肝炎灵注射液致27例不良反应文献分析[J].中华中医药学刊,2008,26(6):1352-135.
[4] 刘梅,刘雪英,程建峰.苦参碱的药理研究进展[J].中国中药杂志,2003,28(9):801-804.
[5] 罗明,贺平,吴孟超,等.苦参碱和氧化苦参碱对二乙基亚硝胺诱发大鼠肝癌作用的影响[J].中国药理学通报,2000,16(4):416-417.
[6] 陈伟忠,张俊平,许青.苦参碱对大鼠实验性肝纤维化的影响[J].第二军医大学学报,1996,7(5):424-426.
[7] 张友祥,张佳发,刘龙民.苦参碱及其有效成分治疗病毒性肝炎作用机理的研究进展[J].上海中医药大学学报,2001,15(2);15:63-65.
[8] 陈伟忠,朱梁,张兴荣,等.苦参碱对大鼠肝纤维化的影响[J].中国新药与临床杂志, 2000,19(5): 410-413.
[9] Zhu X, Qiu Y, Shi M, et al. Matrine protects sinusoidal endo-thelial cells from cold ischemia and reperfusion injury in rat or-thotopic liver transplantation[J]. Ann Clin Lab Sci, 2003,33(2): 216-219.
[10] 邓富良,陈新,吴尚辉, 等.HPLC法测定肝炎灵注射液中苦参碱的含量[J].中药新药与临床药理,2003,14(6):405-407.
[11] 邓鸣,刘会臣.性别对药代动力学的影响[J]. 中国临床药理学杂志,2004,20(1): 68-71.
[12] 朱伟,阮新民,陈可冀.性别差异对大黄酸在人体内药动学过程的影响[J]. 中国临床药理学与治疗学,2006,11(2): 223-226.
[13] 余爱荣,吴笑春,李罄,等.肾移植受者口服环抱素A药代动力学的性别差异[J]. 中国临床药理学与治疗学,2004,9(2): 220-222.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	XU Tao, ZHU Suyan, QIU Xiangjun, XU Ping. Population pharmacokinetics of teicoplanin in patients with renal insufficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 977-983.
[12]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[13]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[14]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[15]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.